- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00817011
Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness (PG)
Phase 4 Study of Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The difficulties to treat depressed patients are 1)the patients don't respond to antidepressant is about 40% of which, and 2) The time lag is existed until the patients respond to antidepressant and show the treatment effects.
If it is predicted the response of antidepressant in advance, it would be overcome such problems. Drug response generally is known to be related to the individual genetic information and the environmental factors. We are going to investigation about antidepressant response using these approaches.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Doh Kwan Kim, M.D.,Ph.D
- Phone Number: 82-2-3410-0946
- Email: jungshil.back@sbri.co.kr
Study Contact Backup
- Name: Shinn-Won Lim, phD
- Phone Number: 82-2-3410-3759
- Email: shinwon.lim@sbri.co.kr
Study Locations
-
-
Seoul
-
Kangnam, Seoul, Korea, Republic of, 135-710
- Recruiting
- Samsung Medical Center
-
Contact:
- DohKwan Kim
-
Principal Investigator:
- Doh Kwan Kim, ph.D, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 25 < age <85
- major depressed patients satisfied with the diagnosis criteria depression of DSM-IV
- interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians
Exclusion Criteria:
- received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks
- potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SSRI treated group
SSRI treated group are depressive patients treated with fluoxetine, paroxetine, citalopram or sertraline
|
Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
Other Names:
|
Active Comparator: non-SSRI treated group
non-SSRI treated group are depressive patients treated with venlafaxine, nortriptyline, bupropion, duloxetine, trazodone or mirtazapine
|
Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
all pharmacogenetic and biological marker variables cause drug response
Time Frame: 24weeks
|
24weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
all clinical cause drug response
Time Frame: 24weeks
|
24weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Doh Kwan Kim, M.D.,Ph.D., Samsung Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Chemically-Induced Disorders
- Depression
- Drug-Related Side Effects and Adverse Reactions
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agents
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Anti-Anxiety Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Serotonin and Noradrenaline Reuptake Inhibitors
- Antidepressive Agents, Tricyclic
- Cytochrome P-450 CYP2D6 Inhibitors
- Serotonin 5-HT3 Receptor Antagonists
- Dopamine Uptake Inhibitors
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Adrenergic Uptake Inhibitors
- Adrenergic alpha-Antagonists
- Adrenergic alpha-2 Receptor Antagonists
- Sertraline
- Duloxetine Hydrochloride
- Citalopram
- Paroxetine
- Bupropion
- Venlafaxine Hydrochloride
- Mirtazapine
- Nortriptyline
- Fluoxetine
- Trazodone
Other Study ID Numbers
- 2006-03-012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on SSRI treated group
-
Centre Hospitalier René DubosCompletedGestational DiabetesFrance
-
Baker Heart Research InstituteNational Health and Medical Research Council, AustraliaUnknown
-
Charles Cornell, MDUnknownEpidermal Thickening, UnspecifiedUnited States
-
University of Texas Southwestern Medical CenterNational Institute of Mental Health (NIMH)CompletedDepressionUnited States
-
Cukurova UniversityCompletedSurgery | Nurse's Role | Thirst | Nausea and Vomiting, Postoperative | Throat, SoreTurkey
-
University of California, Los AngelesBristol-Myers SquibbWithdrawnRheumatoid Arthritis | Apoptotic DNA Damage | T-cell LymphocytosisUnited States
-
Duke UniversityCompletedOsteonecrosisUnited States
-
Hoffmann-La RocheCompletedObsessive-Compulsive DisorderUnited States, Canada
-
Istanbul University - Cerrahpasa (IUC)Completed